Jaundice News and Research

RSS

Jaundice, also known as icterus (attributive adjective: icteric), is a yellowish discoloration of the skin, the conjunctival membranes over the sclerae (whites of the eyes), and other mucous membranes caused by hyperbilirubinemia (increased levels of bilirubin in the blood).

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today the completion of patient enrolment for its first clinical trial.

12 Nov 2013

Neonatal jaundice linked to pediatric asthma risk

Researchers have found that neonatal hyperbilirubinemia is associated with an increased risk for childhood asthma.

7 Nov 2013

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).

5 Nov 2013

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association.

11 Oct 2013

Vaccination campaign led HBV to more than double rate of "breakout" mutations

A universal infant vaccination campaign in China has led the Hepatitis B virus (HBV) to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies.

8 Oct 2013

Mount Sinai physician-scientists join DILIN to help find causes, diagnostics for drug-induced liver injury

In an effort to better understand and develop prevention strategies for drug-induced liver injury, physician-scientists from the Icahn School of Medicine at Mount Sinai have joined the Drug-Induced Liver Injury Network, a National Institutes of Health-funded consortium of only six academic medical centers in the United States.

12 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

65 metabolites in urine simultaneously measured by clinical IEM-by-NMR screening study in Turkey

At the 12th International Congress of Inborn Errors of Metabolism (www.iciem2013.com), Bruker announces another milestone in the cost-effective use of NMR (nuclear magnetic resonance) spectroscopy screening as a clinical research tool for metabolic screening and small molecule in vitro diagnostics (IVD) research and validation.

4 Sep 2013

Delaying umbilical cord clamping after birth benefits newborn babies

Delaying clamping of the umbilical cord after birth benefits newborn babies, according to a systematic review published in The Cochrane Library. The authors found babies’ blood and iron levels were healthier when the cord was clamped later.

12 Jul 2013

Study: More people are being affected by drug-induced liver injury than ever before

More people are being affected by drug-induced liver injury (DILI) than ever before, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

27 Jun 2013

New research reports that UnaG protein could lead to new liver test

Many scientists dream of making a single discovery that provides fundamental insight into nature, may be used to help save human lives, and can assist in the preservation of an endangered species. In new research reported in the journal Cell, a Japanese team is on the verge of accomplishing this nearly impossible feat.

17 Jun 2013

Communication gap between moms and providers in low-income countries puts babies at risk

Mothers in low-income countries may not understand why their babies are hospitalized after delivery, putting sick newborns at higher risk of health problems and death after being released from the hospital, a new study shows.

12 Jun 2013

Discovery highlights protective role of liver enzyme in treating jaundice

Helping to protect newborns and older patients against more severe effects of jaundice is the hope of University of Guelph researchers, who have shown how a liver enzyme protects cells from damage caused by the condition.

10 Jun 2013

Interval between pregnancies: A golden window for obese women to lose weight

The time between pregnancies is a golden window for obese women to lose weight, a Saint Louis University study finds.

4 Jun 2013

WHO: Single dose of vaccination sufficient to confer life-long immunity against yellow fever disease

The yellow fever 'booster' vaccination given ten years after the initial vaccination is not necessary, according to WHO.

17 May 2013

Clitoraid announces first annual International Clitoris Awareness Week

"Clitoraid is proud to announce its first annual International Clitoris Awareness Week, May 6 to May 12," said Nadine Gary , Clitoraid spokesperson, in a statement released today.

5 May 2013

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.

4 May 2013

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype.

25 Apr 2013

Novel approach using Listeria bacteria shows promise against metastatic pancreatic cancer

Researchers at Albert Einstein College of Medicine of Yeshiva University have developed a therapy for pancreatic cancer that uses Listeria bacteria to selectively infect tumor cells and deliver radioisotopes into them.